Oncologists have had a sympathetic hearing from the Pharmaceutical Benefits Advisory Committee (PBAC) on their call to ease the “once in a lifetime” restriction on PD-L1 inhibitors for NSCLC. In a February 2019 meeting to discuss a potential broad NSCLC listing for PD-L1 checkpoint inhibitors, representatives of MOGA said one of the biggest challenges they ...
“Once in a lifetime” restriction may be lifted for checkpoint inhibitors in NSCLC
By Michael Woodhead
15 Apr 2019